Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1671
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17995214 | CD5L-BINDING ANTIBODIES AND USES FOR THE SAME | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18477950 | METHODS OF ASSESSING IMMUNE PROFILE OF A LESION BY IMMUNOIMAGING | Non-Final OA | AMAZON TECHNOLOGIES, INC. |
| 17754258 | COMBINATION TREATMENT FOR CANCER | Non-Final OA | AstraZeneca AB |
| 17791549 | MULTISPECIFIC ANTIBODIES THAT BIND BOTH MAIT AND TUMOR CELLS | Non-Final OA | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) |
| 18277218 | ANTI-DOMAIN IV EGFR ANTIBODIES AND USES THEREOF | Non-Final OA | City of Hope |
| 18084797 | BINDING DOMAINS AGAINST CANCER-ASSOCIATED MUC1 | Non-Final OA | Merus N.V. |
| 18276461 | TCR AND APPLICATION THEREOF | Non-Final OA | LIYANG TCR BIOTHERAPEUTICS CO. LTD |
| 18261489 | ANTI-TRPV6 MONOCLONAL ANTIBODY AND APPLICATION THEREOF | Non-Final OA | COHERENT BIOPHARMA (SUZHOU) , LIMITED |
| 18067230 | ANTIGEN BINDING POLYPEPTIDE COMPLEXES CONTAINING EXTRACELLULAR DOMAINS OF TNFSF LIGANDS | Non-Final OA | ModeX Therapeutics, Inc. |
| 17628920 | COMBINATION THERAPY FOR TREATING RAS-MUTANT CANCERS | Non-Final OA | H. Lee Moffitt Cancer and Research Institute, Inc. |
| 18000674 | CHIMERIC ANTIGEN RECEPTOR TARGETING CLDN18.2 AND USE THEREOF | Final Rejection | SHANGHAI LONGYAO BIOTECHNOLOGY INC., LTD |
| 18000425 | SSTR-2 Binding Chimeric Antigen Receptors | Final Rejection | University of Bari Aldo Moro |
| 17922366 | PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOF | Non-Final OA | Immunorizon Ltd. |
| 17920323 | COMPOSITIONS AND METHODS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | Final Rejection | Edesa Biotech Research, Inc. |
| 17787959 | ANTI-CD 160 BINDING MOLECULES FOR TREATING DISEASES | Non-Final OA | MEDSTAR HEALTH, INC. |
| 17633092 | BISPECIFIC PROTEIN | Final Rejection | ONO PHARMACEUTICAL CO., LTD. |
| 17630854 | NEAR-INFRARED (NIR) PHOTOIMMUNOTHERAPY (PIT) FOR THE TREATMENT OF CANCERS USING ANTI-CD25 ANTIBODY-PHTHALOCYANINE DYE CONJUGATE AND ANTI-PD1 ANTIBODY | Non-Final OA | Rakuten Medical, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy